Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board
Therapeutic Solutions International's pre-spin-off company, Campbell Neurosciences, appoints Raymond Oliver as Chairman of the Board to facilitate its entry into the capital markets. The company plans to distribute up to 10,000,000 shares to existing shareholders in a loyalty dividend. Campbell Neurosciences is focused on developing innovative technologies for the treatment of psychiatric diseases and suicidal propensities.
Appointment of seasoned public company veteran Raymond Oliver as Chairman of the Board to lead the company's public listing strategy.
Plan to offer up to 10,000,000 shares of Campbell Neurosciences' common stock to existing Therapeutic Solutions International shareholders in a loyalty dividend, aiming to accelerate the pathway towards public listing.
Potential dilution of existing shareholders due to the distribution of up to 10,000,000 shares in the form of a loyalty dividend.
Risk associated with the preclinical studies and implementation of new technologies like the CampbellCell and the Campbell Score for psychiatric disease treatment and suicidal propensities.
Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company
Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors. This move is part of a larger strategy the suicide prevention company is implementing towards reaching its goal of a public listing.
“Having worked with Mr. Oliver for more than a decade, I am pleased to say that he possesses a very rare combination of talents: He understands the nuances of public markets, he grasps the complexity of science, and he skillfully weaves the two to raise funds and shareholder value for his client companies,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International and former Chairman and Co-Founder of Campbell Neurosciences. “In my opinion no one is more qualified and talented than Mr. Oliver for this position.”
Campbell Neurosciences was recently issued CUSIP number 13436Q109 for its common shares in anticipation of a public listing. Therapeutic Solutions International plans to offer up to 10,000,000 shares of Campbell Neurosciences’ common stock (restricted) it currently holds to its existing shareholders (as of April 30, 2024) in the form of a loyalty dividend1. This elective grant to TSOI shareholders is anticipated to increase the number of Campbell Neurosciences shareholders, thus accelerating the pathway towards public listing.
“We are completing preclinical studies on the CampbellCell, the first-in-class stem cell product for treatment of psychiatric disease, and beginning implementation of the Campbell Score, a blood/saliva test for suicidal propensities,” said Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences. “Given the urgent need for implementation of these technologies, we are eager to work with Mr. Oliver who has an excellent track record of not only raising funds for public companies, but doing so in a manner that is beneficial and not detrimental in the long-term to shareholders.”
Investor and entrepreneur, Mr. Oliver has assisted companies to get in position for financing and acceleration. Mr. Oliver has been instrumental in sourcing capital for both private and public companies having spent 35 years in the financial markets. Mr. Oliver spent his first 10 years as a Series 7 and 63 licensed retail stockbroker managing all levels of equities markets. Mr. Oliver has spent many years working internally as an executive of multiple public companies. Mr. Oliver’s introductions have resulted in millions of dollars in equity financing in both public and private companies. His capital market specialties include introductions to retail brokers, institutions, money managers, small cap funds, analyst, and others, many having been in his network for over 30 years.
“I am humbled and honored to continue the work of Mr. Timothy Dixon as Chairman of Campbell Neurosciences. Under the guidance of Mr. Dixon, the Company successfully demonstrated efficacy of the Campbell Score in predicting suicidal ideations2, recruited a top-notch advisory board including a founder of a
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 https://www.otcmarkets.com/filing/html?id=17511475&guid=40Q-kqzm3kn4B3h
2 https://classic.clinicaltrials.gov/ct2/show/NCT04606875
3 https://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-titan-of-industry-dr-peter-farrell-joins-advisory-board-of-its-suicide-prevention-spin-off-campbell-neurosciences-301359622.html
4 https://www.businesswire.com/news/home/20231127794359/en/Therapeutic-Solutions-International-and-Campbell-Neurosciences-Publish-on-Nutritional-Modulation-of-the-Indolamine-23-Dioxygenase-Pathway-as-a-Non-Toxic-Means-of-Addressing-Depression
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509561449/en/
Timothy G. Dixon
ir@tsoimail.com
Source: Therapeutic Solutions International, Inc.
FAQ
Who was appointed as Chairman of the Board of Campbell Neurosciences?
What is the planned distribution of shares for Therapeutic Solutions International shareholders?
What technologies is Campbell Neurosciences focused on developing?
